Roche (RHHBY.PK) said the pivotal Phase III study CLL8 showed that patients with previously-untreated chronic lymphocytic leukemia, or CLL, survived their disease longer when treated with Rituxan compared to chemotherapy alone.
The company noted that new data from the Phase III CLL8 study showed that 84.1% of patients with previously untreated CLL who received Rituxan plus fludarabine and cyclophosphamide, or FC, were alive after more than three years of follow up compared to 79.0% of patients who received FC alone. However, the median survival has not yet been reached. After more than three years of follow up, patients who received Rituxan plus FC had a median progression-free survival of 51.8 months compared to 32.8 months for those who received FC alone.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.